Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer

• Sponsor: Dana-Farber Cancer Institute (Other)
• Overall Status: Active, not recruiting
• CT.gov ID: NCT02865811
• Collaborator: Merck Sharp & Dohme LLC (Industry)
• Enrollment: 26
• Locations: 3
• Arm: 1
• Anticipated Duration (Months): 70.5
• Patients Per Site: 8.7
• Patients Per Site Per Month: 0.1

Study Details

Study Description

Brief Summary

This research study is studying the combination of Pegylated Liposomal Doxorubicin (PLD) and Pembrolizumab as a possible treatment for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer that is resistant to platinum therapy.

The following interventions will be used in this study:

• Pegylated liposomal doxorubicin (PLD)

• Pembrolizumab

Condition or Disease	Intervention/Treatment	Phase
Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer	Drug: Pembrolizumab; Drug: Pegylated Liposomal Doxorubicin (PLD)	Phase 2

Detailed Description

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied.

The investigators are looking to see if combining the standard therapy, PLD, and the study drug, Pembrolizumab, will be better than PLD alone. Pembrolizumab is a drug called a monoclonal antibody. Pembrolizumab blocks and interferes with a protein called PD-1; PD-1 can help the cancer cell evade the immune system, and thereby blocking PD-1 may help the immune system recognize and kill cancer cells.

This will be the first time this combination will be tested for participants with Ovarian, Fallopian Tube or Peritoneal Cancer. Therefore, a group of 6 participants will be treated in a "safety lead in" portion of the trial. This lead in will determine the safest dose of PLD when given in combination with the study drug Pembrolizumab. These 6 participants will be treated with Pembrolizumab and PLD at the FDA approved dose to see if the combination is well tolerated or too severe. If the combination is well tolerated, 20 additional participants will be added. If the side effects are too severe, the dose of PLD will be lowered.

The FDA (the U.S. Food and Drug Administration) has approved PLD as a treatment option for this disease, but has not approved Pembrolizumab.

Study Design

• Study Type: Interventional
• Actual Enrollment: 26 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase II Study of Pembrolizumab Combined With Pegylated Liposomal Doxorubicin (PLD) For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer
• Actual Study Start Date: Sep 15, 2016
• Actual Primary Completion Date: Aug 1, 2020
• Anticipated Study Completion Date: Aug 1, 2022

Arms and Interventions

Arm

Intervention/Treatment

Experimental: Pembrolizumab in Combination With PLD A safety lead in with 6 patients will be studied prior the start of the treatment. If 2 out of the first 6 patients develop a dose limiting toxicity (DLT), the dose of PLD will be reduced. If no more than 1 patient of the first 6 patients has evidence of dose limiting toxicities, the dose level will be considered the maximum tolerated dose (MTD) Pegylated Liposomal Doxorubicin (PLD) pre-determine dosage will be administered every 4 weeks via IV Pembrolizumab will be administered as a 30 min IV infusion every 3 weeks at a pre-determine dosage

Drug: Pembrolizumab; Please see "Arms" for description.; Other Names: Keytruda ; Drug: Pegylated Liposomal Doxorubicin (PLD); Please see "Arms" for description.

Outcome Measures

Primary Outcome Measures

1. Clinical Benefit Rate [CBR] [24 Weeks]

   The primary objective was to determine the CBR (complete response [CR] + partial response [PR] + stable disease [SD] >/= 24 weeks) of the combination of pembrolizumab and PLD.

Secondary Outcome Measures

1. Safety of the Combination of Pembrolizumab/PLD [24 weeks]

   Safety is measured by any dose limiting toxicity experienced within the safety lead in group of 6 patients. If 2 out of the first 6 patients develop a DLT, the dose of PLD will be reduced to 30 mg/m2. If no more than 1 patient of the first 6 patients has evidence of dose limiting toxicities, the dose level will be considered the maximum tolerated dose (MTD), an additional 20 patients will be enrolled to complete the phase II study.

2. Overall Response Rate [ORR] [24 months]

   A secondary objective was to determine the Overall Response Rate [ORR] of the combination of pembrolizumab and PLD as defined by the number of participants achieving a partial response [PR] or complete response [CR].

3. Duration of Response [DOR] [24 Months]

   The duration of overall response is measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started, or death due to any cause. Participants without events reported are censored at the last disease evaluation).

4. Progression-Free Survival [PFS] [24 weeks]

   Progression-Free Survival is defined as the time from randomization (or registration) to the earlier of progression or death due to any cause. Participants alive without progression are censored at date of last disease evaluation.

5. Overall Survival [24 Months]

   Overall Survival (OS) is defined as the time from randomization (or registration) to death due to any cause, or censored at date last known alive.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Be willing and able to provide written informed consent/assent for the trial.

• Be 18 years of age on day of signing informed consent.

• Have measurable disease based on RECIST 1.1 criteria.

• Have a histologically confirmed diagnosis of epithelial ovarian cancer, fallopian tube or peritoneal cancer. All histologies of epithelial ovarian cancer are eligible except for carcinosarcomas.

• Patients must have had one prior platinum-based chemotherapeutic regimen for management of primary disease containing carboplatin, cisplatin, or another organoplatinum compound. This initial treatment may have included intraperitoneal therapy, consolidation, biologic/targeted (non-cytotoxic) agents (e.g., bevacizumab) or extended therapy administered after surgical or non-surgical assessment.

• Patients must have platinum resistant cancer with a platinum free interval of < 6 months. Progression after last platinum is based on investigator assessment.

• Patients are allowed to receive, but are not required to receive, up to two additional cytotoxic regimens for management of recurrent or persistent disease, with no more than 1 non-platinum, non-taxane regimen.

• Patients are allowed to receive, but are not required to receive, biologic/targeted (non-cytotoxic) therapy as part of their primary treatment regimen. For the purposes of this study, Poly (ADP-ribose) polymerase (PARP) inhibitors will be considered "cytotoxic." Patients are allowed to receive, but are not required to receive, PARP inhibitors for management of primary or recurrent/persistent disease (either alone or in combination with cytotoxic chemotherapy). Single agent hormonal therapies will not be counted as a line of treatment.

• Have adequate tissue from an archived specimen of ovarian cancer (between 10 to 15 slides of unstained tumor).

• Have a performance status of 0 or 1 on the ECOG Performance Scale (Appendix A).

• Demonstrate adequate organ function as defined in Table 1, all screening labs must be performed within 10 days of treatment initiation.

Table 1 Adequate Organ Function Laboratory Values

System Laboratory Value

• Hematological

• Absolute neutrophil count (ANC) ≥1,500 /mcL

• Platelets ≥100,000 / mcL

• Hemoglobin ≥9 g/dL or ≥5.6 mmol/L without transfusion or EPO dependency (within 7 days of assessment)

• Renal

• Serum creatinine OR

• Measured or calculated creatinine clearance (GFR can also be used in place of creatinine or CrCl) ≤1.5 X upper limit of normal (ULN) OR ≥60 mL/min for participant with creatinine levels > 1.5 X institutional ULN

• Hepatic

• Serum total bilirubin ≤ 1.5 X ULN OR Direct bilirubin ≤ ULN for participants with total bilirubin levels > 1.5 ULN

• AST (SGOT) and ALT (SGPT) ≤ 2.5 X ULN OR ≤ 5 X ULN for participants with liver metastases

• Albumin >2.5 mg/dL

• Coagulation

• International Normalized Ratio (INR) or Prothrombin Time (PT)

• Activated Partial Thromboplastin Time (aPTT) ≤1.5 X ULN unless participant is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants ≤1.5 X ULN unless participant is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants aCreatinine clearance should be calculated per institutional standard.

• Female participants of childbearing potential must have a negative serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.

• Female participants of childbearing potential must be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication. Participants of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year.

Exclusion Criteria:

• Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.

• Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.

• Patients cannot have primary platinum refractory cancer, i.e. documented cancer progression while receiving platinum or within one month of receipt of a platinum based regimen.

• Has received a prior anthracycline chemotherapy either for ovarian cancer treatment or another previous malignancy.

• Left ventricular ejection fraction (LVEF) defined by multigated acquisition (MUGA) or echocardiogram which is below the institutional lower limit of normal prior to starting study treatment.

• Has a known history of active TB (Bacillus Tuberculosis)

• Hypersensitivity to pembrolizumab or any of its excipients and/or liposomal doxorubicin.

• Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.

• Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent.

• Note: Participants with < Grade 2 neuropathy are an exception to this criterion and may qualify for the study.

• Note: If participant underwent major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.

• Has a known additional malignancy that is progressing or requires active treatment. In addition, patients cannot have been diagnosed with another malignancy within 3 years of starting treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.

• Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment. This exception does not include clinically active and significant carcinomatous meningitis which is excluded regardless of clinical stability.

• Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.

• Has known history of, or any evidence of active, non-infectious pneumonitis.

• Has an active infection requiring systemic therapy.

• Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the participant's participation for the full duration of the trial, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.

• Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.

• Is pregnant or breastfeeding, or expecting to conceive within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.

• Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.

• Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).

• Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).

• Has received a live vaccine within 30 days of planned start of study therapy.

• Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Massachusetts General Hospital	Boston	Massachusetts	United States	02114
2	Dana Farber Cancer Institute	Boston	Massachusetts	United States	02115
3	Northwell Hospital Monter Cancer Center	Lake Success	New York	United States	11042

Sponsors and Collaborators

• Dana-Farber Cancer Institute
• Merck Sharp & Dohme LLC

Investigators

• Principal Investigator: Ursula Matulonis, MD, Dana-Farber Cancer Institute

Study Documents (Full-Text)

• Study Protocol and Statistical Analysis Plan - Aug 29, 2018

More Information

Publications

None provided.

• Responsible Party: Ursula A. Matulonis, MD, MD, Dana-Farber Cancer Institute
• ClinicalTrials.gov Identifier: NCT02865811
• Other Study ID Numbers: 16-257
• First Posted: Aug 12, 2016
• Last Update Posted: Oct 1, 2021
• Last Verified: Sep 1, 2021

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Keywords provided by Ursula A. Matulonis, MD, MD, Dana-Farber Cancer Institute: Ovarian Cancer
• Additional relevant MeSH terms: Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Doxorubicin; Liposomal doxorubicin; Pembrolizumab

Study Results

Participant Flow

Arm/Group Title	Pembrolizumab in Combination With PLD
Arm/Group Description	A safety lead in with 6 patients will be studied prior the start of the treatment. If 2 out of the first 6 patients develop a dose limiting toxicity (DLT), the dose of PLD will be reduced. If no more than 1 patient of the first 6 patients has evidence of dose limiting toxicities, the dose level will be considered the maximum tolerated dose (MTD) Pegylated Liposomal Doxorubicin (PLD) pre-determine dosage will be administered every 4 weeks via IV Pembrolizumab will be administered as a 30 min IV infusion every 3 weeks at a pre-determine dosag
Period Title: Overall Study
STARTED	26
COMPLETED	26
NOT COMPLETED	0

Baseline Characteristics

Arm/Group Title	Pembrolizumab in Combination With PLD
Arm/Group Description	A safety lead in with 6 patients will be studied prior the start of the treatment. If 2 out of the first 6 patients develop a dose limiting toxicity (DLT), the dose of PLD will be reduced. If no more than 1 patient of the first 6 patients has evidence of dose limiting toxicities, the dose level will be considered the maximum tolerated dose (MTD) Pegylated Liposomal Doxorubicin (PLD) pre-determine dosage will be administered every 4 weeks via IV Pembrolizumab will be administered as a 30 min IV infusion every 3 weeks at a pre-determine dosag
Overall Participants	26
Age (years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [years]	59.4 (11.3)
Age, Customized (years) [Median (Full Range) ]
Median (Full Range) [years]	60.0
Sex: Female, Male (Count of Participants)
Female	26 100%
Male	0 0%
Ethnicity (NIH/OMB) (Count of Participants)
Hispanic or Latino	0 0%
Not Hispanic or Latino	23 88.5%
Unknown or Not Reported	3 11.5%
Race (NIH/OMB) (Count of Participants)
American Indian or Alaska Native	0 0%
Asian	3 11.5%
Native Hawaiian or Other Pacific Islander	0 0%
Black or African American	0 0%
White	22 84.6%
More than one race	1 3.8%
Unknown or Not Reported	0 0%
Stage at Initial Diagnosis (Count of Participants)
Stage I	2 7.7%
Stage II	1 3.8%
Stage III	12 46.2%
Stage IV	10 38.5%
Missing	1 3.8%
Differentiation (Grade) (Count of Participants)
Well Differentiated	1 3.8%
Moderately Differentiated	1 3.8%
Poorly Differentiated	21 80.8%
Missing	3 11.5%
Histology (Count of Participants)
Adenocarcinoma, not further specified	1 3.8%
Serous	20 76.9%
Clear Cell	2 7.7%
Mucinous	2 7.7%
Mixed serous/mucinous	1 3.8%
ECOG Performance Status (Count of Participants)
0- Fully Active	16 61.5%
1- Restricted	10 38.5%
# of Prior Lines (Count of Participants)
1	10 38.5%
2	10 38.5%
3	6 23.1%
Platinum Free Interval (PFI) (Count of Participants)
<3 Months	7 26.9%
3-6 Months	19 73.1%

Outcome Measures

1. Primary Outcome

Title	Clinical Benefit Rate [CBR]
Description	The primary objective was to determine the CBR (complete response [CR] + partial response [PR] + stable disease [SD] >/= 24 weeks) of the combination of pembrolizumab and PLD.
Time Frame	24 Weeks

Outcome Measure Data

Analysis Population Description

Of the 26 patients enrolled, 23 patients were evaluable for objective response by RECIST.

Arm/Group Title	Pembrolizumab in Combination With PLD
Arm/Group Description	A safety lead in with 6 patients will be studied prior the start of the treatment. If 2 out of the first 6 patients develop a dose limiting toxicity (DLT), the dose of PLD will be reduced. If no more than 1 patient of the first 6 patients has evidence of dose limiting toxicities, the dose level will be considered the maximum tolerated dose (MTD) Pegylated Liposomal Doxorubicin (PLD) pre-determine dosage will be administered every 4 weeks via IV Pembrolizumab will be administered as a 30 min IV infusion every 3 weeks at a pre-determine dosage Pembrolizumab: Please see "Arms" for description. Pegylated Liposomal Doxorubicin (PLD): Please see "Arms" for description.
Measure Participants	23
Count of Participants [Participants]	12 46.2%

2. Secondary Outcome

Title	Safety of the Combination of Pembrolizumab/PLD
Description	Safety is measured by any dose limiting toxicity experienced within the safety lead in group of 6 patients. If 2 out of the first 6 patients develop a DLT, the dose of PLD will be reduced to 30 mg/m2. If no more than 1 patient of the first 6 patients has evidence of dose limiting toxicities, the dose level will be considered the maximum tolerated dose (MTD), an additional 20 patients will be enrolled to complete the phase II study.
Time Frame	24 weeks

Outcome Measure Data

Analysis Population Description

6 patients were included in the safety lead-in group

Arm/Group Title	Pembrolizumab in Combination With PLD
Arm/Group Description	A safety lead in with 6 patients will be studied prior the start of the treatment. If 2 out of the first 6 patients develop a dose limiting toxicity (DLT), the dose of PLD will be reduced. If no more than 1 patient of the first 6 patients has evidence of dose limiting toxicities, the dose level will be considered the maximum tolerated dose (MTD) Pegylated Liposomal Doxorubicin (PLD) pre-determine dosage will be administered every 4 weeks via IV Pembrolizumab will be administered as a 30 min IV infusion every 3 weeks at a pre-determine dosag
Measure Participants	6
Count of Participants [Participants]	1 3.8%

3. Secondary Outcome

Title	Overall Response Rate [ORR]
Description	A secondary objective was to determine the Overall Response Rate [ORR] of the combination of pembrolizumab and PLD as defined by the number of participants achieving a partial response [PR] or complete response [CR].
Time Frame	24 months

Outcome Measure Data

Analysis Population Description

Of the 26 patients enrolled, 23 patients were evaluable for objective response by RECIST.

Arm/Group Title	Pembrolizumab in Combination With PLD
Arm/Group Description	A safety lead in with 6 patients will be studied prior the start of the treatment. If 2 out of the first 6 patients develop a dose limiting toxicity (DLT), the dose of PLD will be reduced. If no more than 1 patient of the first 6 patients has evidence of dose limiting toxicities, the dose level will be considered the maximum tolerated dose (MTD) Pegylated Liposomal Doxorubicin (PLD) pre-determine dosage will be administered every 4 weeks via IV Pembrolizumab will be administered as a 30 min IV infusion every 3 weeks at a pre-determine dosag
Measure Participants	23
Partial Response	5 19.2%
Complete Reponse	1 3.8%

4. Secondary Outcome

Title	Duration of Response [DOR]
Description	The duration of overall response is measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started, or death due to any cause. Participants without events reported are censored at the last disease evaluation).
Time Frame	24 Months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Pembrolizumab in Combination With PLD
Arm/Group Description	A safety lead in with 6 patients will be studied prior the start of the treatment. If 2 out of the first 6 patients develop a dose limiting toxicity (DLT), the dose of PLD will be reduced. If no more than 1 patient of the first 6 patients has evidence of dose limiting toxicities, the dose level will be considered the maximum tolerated dose (MTD) Pegylated Liposomal Doxorubicin (PLD) pre-determine dosage will be administered every 4 weeks via IV Pembrolizumab will be administered as a 30 min IV infusion every 3 weeks at a pre-determine dosag
Measure Participants	26
Median (95% Confidence Interval) [months]	10.58

5. Secondary Outcome

Title	Progression-Free Survival [PFS]
Description	Progression-Free Survival is defined as the time from randomization (or registration) to the earlier of progression or death due to any cause. Participants alive without progression are censored at date of last disease evaluation.
Time Frame	24 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Pembrolizumab in Combination With PLD
Arm/Group Description	A safety lead in with 6 patients will be studied prior the start of the treatment. If 2 out of the first 6 patients develop a dose limiting toxicity (DLT), the dose of PLD will be reduced. If no more than 1 patient of the first 6 patients has evidence of dose limiting toxicities, the dose level will be considered the maximum tolerated dose (MTD) Pegylated Liposomal Doxorubicin (PLD) pre-determine dosage will be administered every 4 weeks via IV Pembrolizumab will be administered as a 30 min IV infusion every 3 weeks at a pre-determine dosag
Measure Participants	26
Progression events defined by RECIST 1.1	8.1
Progression events defined by RECIST 1.1 and clinical progression	5.6

6. Secondary Outcome

Title	Overall Survival
Description	Overall Survival (OS) is defined as the time from randomization (or registration) to death due to any cause, or censored at date last known alive.
Time Frame	24 Months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Pembrolizumab in Combination With PLD
Arm/Group Description	A safety lead in with 6 patients will be studied prior the start of the treatment. If 2 out of the first 6 patients develop a dose limiting toxicity (DLT), the dose of PLD will be reduced. If no more than 1 patient of the first 6 patients has evidence of dose limiting toxicities, the dose level will be considered the maximum tolerated dose (MTD) Pegylated Liposomal Doxorubicin (PLD) pre-determine dosage will be administered every 4 weeks via IV Pembrolizumab will be administered as a 30 min IV infusion every 3 weeks at a pre-determine dosag
Measure Participants	26
Median (95% Confidence Interval) [months]	18.3

Adverse Events

Time Frame	Adverse Events (AEs) were collected weekly throughout study participation for all patients, and for 4 weeks after treatment completion.
Adverse Event Reporting Description	Expedited reporting applied to any medical event equivalent to an unexpected grade 2 or 3 with a possible, probable or definite attribution, both expected (unless listed in the protocol as not requiring expedited reporting) and unexpected grade 4 toxicities, and grade 5 (death) regardless of study phase or attribution.
Arm/Group Title	Pembrolizumab in Combination With PLD
Arm/Group Description	A safety lead in with 6 patients will be studied prior the start of the treatment. If 2 out of the first 6 patients develop a dose limiting toxicity (DLT), the dose of PLD will be reduced. If no more than 1 patient of the first 6 patients has evidence of dose limiting toxicities, the dose level will be considered the maximum tolerated dose (MTD) Pegylated Liposomal Doxorubicin (PLD) pre-determine dosage will be administered every 4 weeks via IV Pembrolizumab will be administered as a 30 min IV infusion every 3 weeks at a pre-determine dosag
All Cause Mortality
	Pembrolizumab in Combination With PLD
	Affected / at Risk (%)	# Events
Total	0/26 (0%)
Serious Adverse Events
	Pembrolizumab in Combination With PLD
	Affected / at Risk (%)	# Events
Total	3/26 (11.5%)
Investigations
Alanine aminotransferase increased	1/26 (3.8%)	2
Alkaline phosphatase increased	1/26 (3.8%)	2
Nervous system disorders
Seizure	1/26 (3.8%)	1
Renal and urinary disorders
Acute kidney injury	1/26 (3.8%)	1
Other (Not Including Serious) Adverse Events
	Pembrolizumab in Combination With PLD
	Affected / at Risk (%)	# Events
Total	26/26 (100%)
Blood and lymphatic system disorders
Anemia	9/26 (34.6%)
Blood and lymphatic system disorders - Other, specify	1/26 (3.8%)
Cardiac disorders
Atrial fibrillation	1/26 (3.8%)
Palpitations	1/26 (3.8%)
Sinus tachycardia	1/26 (3.8%)
Endocrine disorders
Hypothyroidism	3/26 (11.5%)
Endocrine disorders - Other, specify	1/26 (3.8%)
Hyperthyroidism	1/26 (3.8%)
Eye disorders
Dry eye	1/26 (3.8%)
Gastrointestinal disorders
Abdominal pain	11/26 (42.3%)
Nausea	10/26 (38.5%)
Vomiting	10/26 (38.5%)
Constipation	8/26 (30.8%)
Gastrointestinal disorders - Other, specify	7/26 (26.9%)
Dyspepsia	5/26 (19.2%)
Mucositis oral	4/26 (15.4%)
Ascites	4/26 (15.4%)
Small intestinal obstruction	4/26 (15.4%)
Oral pain	3/26 (11.5%)
Abdominal distension	2/26 (7.7%)
Bloating	2/26 (7.7%)
Fecal incontinence	2/26 (7.7%)
Gastroesophageal reflux disease	2/26 (7.7%)
Dry mouth	1/26 (3.8%)
Flatulence	1/26 (3.8%)
Gastroparesis	1/26 (3.8%)
Hemorrhoids	1/26 (3.8%)
Oral dysesthesia	1/26 (3.8%)
Rectal hemorrhage	1/26 (3.8%)
Colitis	1/26 (3.8%)
Colonic obstruction	1/26 (3.8%)
General disorders
Fatigue	13/26 (50%)
Diarrhea	7/26 (26.9%)
Fever	5/26 (19.2%)
Pain	5/26 (19.2%)
Infusion related reaction	3/26 (11.5%)
Non-cardiac chest pain	3/26 (11.5%)
Edema limbs	2/26 (7.7%)
Chills	1/26 (3.8%)
General disorders and administration site conditions - Other, specify	1/26 (3.8%)
Immune system disorders
Allergic reaction	1/26 (3.8%)
Infections and infestations
Infections and infestations - Other, specify	7/26 (26.9%)
Urinary tract infection	4/26 (15.4%)
Upper respiratory infection	3/26 (11.5%)
Skin infection	2/26 (7.7%)
Mucosal infection	2/26 (7.7%)
Sinusitis	1/26 (3.8%)
Vaginal infection	1/26 (3.8%)
Sepsis	1/26 (3.8%)
Injury, poisoning and procedural complications
Injury, poisoning and procedural complications - Other, specify	1/26 (3.8%)
Urostomy obstruction	1/26 (3.8%)
Investigations
Aspartate aminotransferase increased	8/26 (30.8%)
Alanine aminotransferase increased	5/26 (19.2%)
Alkaline phosphatase increased	5/26 (19.2%)
Neutrophil count decreased	5/26 (19.2%)
Platelet count decreased	5/26 (19.2%)
Blood bilirubin increased	2/26 (7.7%)
Creatinine increased	2/26 (7.7%)
Lymphocyte count decreased	1/26 (3.8%)
Weight loss	1/26 (3.8%)
Metabolism and nutrition disorders
Hyponatremia	7/26 (26.9%)
Hypoalbuminemia	4/26 (15.4%)
Hypocalcemia	4/26 (15.4%)
Hypokalemia	4/26 (15.4%)
Hypomagnesemia	4/26 (15.4%)
Anorexia	3/26 (11.5%)
Hyperglycemia	3/26 (11.5%)
Dehydration	3/26 (11.5%)
Hypophosphatemia	2/26 (7.7%)
Musculoskeletal and connective tissue disorders
Myalgia	4/26 (15.4%)
Back pain	3/26 (11.5%)
Neck pain	2/26 (7.7%)
Arthralgia	1/26 (3.8%)
Arthritis	1/26 (3.8%)
Bone pain	1/26 (3.8%)
Musculoskeletal and connective tissue disorder - Other, specify	1/26 (3.8%)
Myositis	1/26 (3.8%)
Pain in extremity	1/26 (3.8%)
Flank pain	1/26 (3.8%)
Nervous system disorders
Headache	2/26 (7.7%)
Paresthesia	1/26 (3.8%)
Peripheral sensory neuropathy	1/26 (3.8%)
Syncope	1/26 (3.8%)
Dysgeusia	1/26 (3.8%)
Seizure	1/26 (3.8%)
Psychiatric disorders
Confusion	2/26 (7.7%)
Insomnia	1/26 (3.8%)
Renal and urinary disorders
Acute kidney injury	2/26 (7.7%)
Urinary urgency	2/26 (7.7%)
Urinary incontinence	1/26 (3.8%)
Bladder spasm	1/26 (3.8%)
Reproductive system and breast disorders
Pneumonitis	2/26 (7.7%)
Pelvic pain	1/26 (3.8%)
Vaginal discharge	1/26 (3.8%)
Vaginal dryness	1/26 (3.8%)
Respiratory, thoracic and mediastinal disorders
Dyspnea	7/26 (26.9%)
Cough	4/26 (15.4%)
Sore throat	2/26 (7.7%)
Epistaxis	1/26 (3.8%)
Nasal congestion	1/26 (3.8%)
Pleural effusion	1/26 (3.8%)
Skin and subcutaneous tissue disorders
Rash maculo-papular	10/26 (38.5%)
Skin/subcutaneous tissue disorders; Other, specify	8/26 (30.8%)
Palmar-plantar erythrodysesthesia syndrome	4/26 (15.4%)
Dry skin	2/26 (7.7%)
Pruritus	2/26 (7.7%)
Skin hyperpigmentation	2/26 (7.7%)
Alopecia	1/26 (3.8%)
Nail discoloration	1/26 (3.8%)
Photosensitivity	1/26 (3.8%)
Telangiectasia	1/26 (3.8%)
Urticaria	1/26 (3.8%)
Vascular disorders
Hypertension	3/26 (11.5%)
Hypotension	1/26 (3.8%)
Thromboembolic event	1/26 (3.8%)

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

All Principal Investigators ARE employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.